Hyloris Pharmaceuticals SA (HYL.BR)

EUR 6.48

(-0.34%)

Total Liabilities Summary of Hyloris Pharmaceuticals SA

  • Hyloris Pharmaceuticals SA's latest annual total liabilities in 2023 was 8.61 Million EUR , up 26.29% from previous year.
  • Hyloris Pharmaceuticals SA's latest quarterly total liabilities in 2023 FY was 8.61 Million EUR , up 26.29% from previous quarter.
  • Hyloris Pharmaceuticals SA reported annual total liabilities of 6.81 Million EUR in 2022, down -55.69% from previous year.
  • Hyloris Pharmaceuticals SA reported annual total liabilities of 15.38 Million EUR in 2021, up 52.01% from previous year.
  • Hyloris Pharmaceuticals SA reported quarterly total liabilities of 8.61 Million EUR for 2023 Q3, up 0.73% from previous quarter.
  • Hyloris Pharmaceuticals SA reported quarterly total liabilities of 8.55 Million EUR for 2023 Q1, up 25.38% from previous quarter.

Annual Total Liabilities Chart of Hyloris Pharmaceuticals SA (2023 - 2016)

Historical Annual Total Liabilities of Hyloris Pharmaceuticals SA (2023 - 2016)

Year Total Liabilities Total Liabilities Growth
2023 8.61 Million EUR 26.29%
2022 6.81 Million EUR -55.69%
2021 15.38 Million EUR 52.01%
2020 10.12 Million EUR -37.4%
2019 16.17 Million EUR 30.31%
2018 12.41 Million EUR 43.45%
2017 8.65 Million EUR 144.86%
2016 3.53 Million EUR 0.0%

Peer Total Liabilities Comparison of Hyloris Pharmaceuticals SA

Name Total Liabilities Total Liabilities Difference
Nicox S.A. 31.56 Million EUR 72.718%
European Medical Solutions 33.86 Million EUR 74.57%
FERMENTALG 19.39 Million EUR 55.604%
argenx SE 402.79 Million EUR 97.862%
BioSenic S.A. 32.26 Million EUR 73.308%
Celyad Oncology SA 9.97 Million EUR 13.69%
Onward Medical N.V. 25.69 Million EUR 66.488%
Oxurion NV 19.73 Million EUR 56.364%
PHAXIAM Therapeutics S.A. 25.69 Million EUR 66.484%
Financière de Tubize SA 123.65 Million EUR 93.035%
UCB SA 6.56 Billion EUR 99.869%